九洲药业
(603456)
| 流通市值：116.56亿 | | | 总市值：116.56亿 |
| 流通股本：8.95亿 | | | 总股本：8.95亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,965,261,223.17 | 2,764,279,820.31 | 1,475,743,576.44 | 5,523,418,175.43 |
| 营业收入 | 3,965,261,223.17 | 2,764,279,820.31 | 1,475,743,576.44 | 5,523,418,175.43 |
| 二、营业总成本 | 3,190,787,304.91 | 2,176,923,770.53 | 1,168,180,070.26 | 4,275,834,833.86 |
| 营业成本 | 2,587,368,120.12 | 1,790,907,120.13 | 973,336,263.69 | 3,443,493,393.32 |
| 税金及附加 | 40,089,787.46 | 31,781,297.47 | 20,367,756.91 | 49,204,012.1 |
| 销售费用 | 72,344,977.48 | 43,892,002.85 | 20,156,806.67 | 82,017,748.26 |
| 管理费用 | 300,560,133.5 | 197,947,419.63 | 108,335,352.12 | 445,926,655.97 |
| 研发费用 | 240,137,612.13 | 160,008,049.72 | 64,871,910.84 | 330,827,761.17 |
| 财务费用 | -49,713,325.78 | -47,612,119.27 | -18,888,019.97 | -75,634,736.96 |
| 其中:利息费用 | 16,307,011.53 | 14,233,916.01 | 8,070,432.96 | 21,733,602.9 |
| 其中:利息收入 | 72,828,114.9 | 57,715,485.93 | 26,450,493.61 | 91,824,261.69 |
| 加:投资收益 | -4,629,630.62 | -5,328,237.59 | -2,341,966.21 | -19,363,697.54 |
| 资产处置收益 | -2,099,975.26 | -2,811,070.01 | -2,172,342.18 | -2,543,160.71 |
| 资产减值损失(新) | -38,630,224.5 | -26,268,486.77 | -108,206.84 | -78,203,593.39 |
| 信用减值损失(新) | -12,933,546.38 | -21,984,102.86 | -33,969,218.86 | -20,173,755.07 |
| 其他收益 | 30,919,535.52 | 23,710,282.3 | 11,114,786.63 | 48,472,250.12 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 747,100,077.02 | 554,674,434.85 | 280,086,558.72 | 1,175,771,384.98 |
| 加:营业外收入 | 651,393.57 | 580,391.26 | 16,616.01 | 8,023,633.72 |
| 减:营业外支出 | 1,041,692.65 | 384,163.07 | 61,133.27 | 3,152,981.13 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 746,709,777.94 | 554,870,663.04 | 280,042,041.46 | 1,180,642,037.57 |
| 减:所得税费用 | 113,857,286.13 | 79,257,105.79 | 43,869,153.92 | 149,270,261.88 |
| 六、净利润 | 632,852,491.81 | 475,613,557.25 | 236,172,887.54 | 1,031,371,775.69 |
| 持续经营净利润 | 632,852,491.81 | 475,613,557.25 | 236,172,887.54 | 1,031,371,775.69 |
| 归属于母公司股东的净利润 | 630,876,705.82 | 474,988,640.43 | 236,758,875.39 | 1,033,255,687.14 |
| 少数股东损益 | 1,975,785.99 | 624,916.82 | -585,987.85 | -1,883,911.45 |
| (一)基本每股收益 | 0.7 | 0.53 | 0.26 | 1.16 |
| (二)稀释每股收益 | 0.7 | 0.53 | 0.26 | 1.16 |
| 八、其他综合收益 | -3,871,050.78 | 1,710,782.56 | 2,362,921.59 | 2,052,331.71 |
| 归属于母公司股东的其他综合收益 | -3,871,050.78 | 1,710,782.56 | 2,362,921.59 | 2,052,331.71 |
| 九、综合收益总额 | 628,981,441.03 | 477,324,339.81 | 238,535,809.13 | 1,033,424,107.4 |
| 归属于母公司股东的综合收益总额 | 627,005,655.04 | 476,699,422.99 | 239,121,796.98 | 1,035,308,018.85 |
| 归属于少数股东的综合收益总额 | 1,975,785.99 | 624,916.82 | -585,987.85 | -1,883,911.45 |
| 公告日期 | 2024-10-25 | 2024-08-27 | 2024-04-25 | 2024-04-09 |
| 审计意见(境内) | | | | 标准无保留意见 |